Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.73 |
| ▸ | FAAH | O00519 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967782 | 0.86 | MPO (1.00) | MPOFAAHKDM4EALDH1A1LMNA | |
| SCHEMBL21043991 | 0.83 | MPO (0.73) | MPOFAAHKDM4EALDH1A1LMNA | |
| SCHEMBL14939397 | 0.83 | ALDH1A1 (0.54) | MPOFAAHKDM4EALDH1A1LMNA | |
| SCHEMBL3599605 | 0.82 | FAAH (1.00) | FAAHKDM4E | |
| SCHEMBL2931693 | 0.82 | FAAH (0.70) | FAAHKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3098473 | 0.82 | ALDH1A1 (0.70) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL21658466 | 0.81 | MPO (0.81) | MPOFAAHKDM4EALDH1A1LMNA | |
| SCHEMBL23293594 | 0.81 | HTR7 (0.63) | FAAHKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL16731676 | 0.81 | MPO (0.69) | MPOFAAHKDM4EALDH1A1LMNA | |
| SCHEMBL9388542 | 0.80 | MPO (0.88) | MPOFAAHKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3814347-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-102482232-A | Novel pyrimidine and triazine hepcidin antagonists | VIFOR INT AG | 2012-05-30 | — | — | CN | disclosed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | MPO 1182/4885FAAH 24/4885KDM4E 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.